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Abstract
This is a literature review that used as database articles in websites 
like Bireme, SciELO, LILACS, Journals and Webartigos. 
Development: Trachoma is an ocular inflammatory disease, whose 
etiological agent is Chlamydia trachomatis, which affects the con-
junctiva and cornea causing a chronic relapsing keratoconjunctivitis, 
in the course of time may lead to the formation of entropion, tri-
chiasis and possible blindness. Its transmission occurs in the home 
environment, directly or indirectly. The occurrence of trachoma is 
mostly where hygiene and lifestyle habits are precarious. According 
to the World Health Organization, there are six million people cu-
rrently infected. 
Conclusion: The study shows the importance of knowledge about 
trachoma, so that Brazil is able to achieve the global goal of elimina-
ting the disease by 2020.
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Although millenary known, Trachoma is still one of the diseases of 
concern to the world, and is present especially in developing countries. 
In 2003, the World Health Organization (WHO) estimated that there 
are 84 million people with active trachoma in the world, 76 million 
with trachoma trichiasis and five million with serious risks for their 
vision and potential development of blindness. Moreover, 80 million 
children had inflammatory trachoma that could potentially cause se-
vere visual impairment [1, 2].
The word trachoma (Greek Tráchomas) means rough, lumpy or swo-
llen, describing the appearance of the tarsal conjunctiva affected. Tra-
InternatIonal archIves of MedIcIne 
sectIon: ophtalMology
ISSN: 1755-7682
2017
Vol. 10 No. 56
doi: 10.3823/2326
This article is available at: www.intarchmed.com and www.medbrary.com 2
choma is the etiological agent caused by Chlamydia 
trachomatis, gram-negative, low infectivity, but its 
distribution in the world is wide. Natural or acquired 
immunity to the infection by this bacterium is not 
verified [3].
Trachoma is considered by the international 
health organizations a neglected disease, and since 
others are also classified as such, there is little or 
no investment by the industry in the development 
of new diagnostic techniques, drugs, vaccines, and 
is also neglected by Colleges, which can be seen 
by the small number of studies and publications. 
(4) Is included among the causes of blindness that 
can be prevented by making part of the GET 2020 
(Global Elimination of Trachoma) of WHO, which 
aims to eliminate preventable causes of blindness 
in the world by the year 2020 [4, 5]
It is considered an inflammatory eye disease a 
relapsing chronic keratoconjunctivitis that with the 
course of time, produces scars on the upper eye-
lid conjunctiva, which may lead to the formation 
of entropion (eyelid with the turn-edge in the eye) 
and trichiasis (eyelash in faulty position the edges 
eyelid, touching the eyeball). The active, infectious 
stage takes place predominantly at preschool age 
with blindness risks in the future in these highly 
endemic areas. The scarring inactive phase is found 
in adults [6].
The diagnosis of trachoma is essentially clinical, 
evaluating changes of the eyelids, eyelashes, tarsal 
and bulbar conjunctiva and cornea. The upper eye-
lids are everted and the upper conjunctiva carefully 
examined. WHO advises that the diagnosis of tra-
choma should be given when at least two of the 
following clinical signs are present: follicles on the 
upper tarsal conjunctiva, follicles in limbo or pits 
Herbert, typical conjunctival scarring and pannus in 
the upper limb [4, 7] 
Methods
This research has nature of literature review, using 
articles from the years 2001-2014, the databases of 
the websites Bireme, SciELO, LILACS, Journals and 
virtual articles. In addition, academic books and ma-
nuals updated the Ministry of Health were used.
Literature Review
Disease History
Trachoma is the second cause of blindness in the 
world, keeping itself in hyperendemic levels in va-
rious regions, such as Asia, Africa and the Middle 
East.
In the Americas, there are several outbreaks in 
the region located in southern Mexico, Guatemala, 
Bolivia, Peru and northeastern Brazil [8, 9].
The first citations of this eye disorder were in 
1556 B.C, on a papyrus in the ancient scriptures it 
was discovered only in 1892 by George Ehers. The 
disease came to be described in Egypt in 525 B.C 
during the Persian invasion, and in 48 BC, Cicero 
said that in Rome several doctors cured the trichia-
sis, trachoma and performed cataract operations 
[6-9].
The occurrence of trachoma has increased consi-
derably with the masses and hygiene conditions of 
these environments with the end of the Agricultural 
Revolution and the beginning of the Industrial Re-
volution (10). Over the past century, trachoma was 
highly prevalent in Europe and North America and 
was the main cause of blindness in those regions. 
Trachoma disappearance of developed countries 
has been accelerated by the introduction of sulfa 
drugs in 1930 and antibiotics in the 1940s (10). In 
this century, the disease was gradually disappea-
ring due to multiple changes in living conditions and 
health care [6, 9].
In Brazil, trachoma arrived in the eighteenth cen-
tury between 1718 and 1750, with the colonization 
of Portuguese and Europeans, because until then 
the disease did not exist in the native populations 
of the country. It was developed initially in the Nor-
theast, specifically in Cariri in Ceará, where there is 
the oldest outbreak of disease in Brazil. In addition 
to this, two other outbreaks contributed decisively 
to the spread of trachoma: Rio Grande do Sul and 
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São Paulo. Both started in the late nineteenth cen-
tury also with the colonization of foreigners coming 
from endemic countries of the Mediterranean (Italy 
and Spain), expanding to other regions [6, 9, 11].
The first measure of control Trachoma adopted 
in Brazil was the initiative of the Government of the 
State of São Paulo, which in 1904 banned the entry 
of immigrants with trachoma in the Port of Santos, 
similar to what was done in the United States. But 
this measure was not successful, due to pressure 
from the coffee farmers, in need of immigrant labor. 
Thus, the ban was replaced by a fine to the owner 
of the ship that brought immigrants with trachoma 
[4].
In the national level, the first control measure was 
taken in 1923 when enacted the "Regulations of 
the National Department of Public Health, " which 
prohibited the landing of immigrants with tracho-
ma. A measure that was taken after such a long 
time because back then the disease found itself wi-
despread in the country and no longer depended 
on immigration to maintain this condition [4].
But only in 1990, trachoma control activities at 
a national level became part of the duties of the 
National Health Foundation - FNS and until today, 
the Ministry of Health has maintained control ac-
tions in regions with higher prevalence, through 
FNS. However, the idea of eradicating trachoma 
still remains dominant among the Brazilian scientific 
community [4, 12].
The occurrence of trachoma in the world today 
is restricted almost exclusively to the populations of 
developing countries and within them, the rural and 
poor population, marginalized from the benefits of 
socioeconomic development. The World Health Or-
ganization (WHO) points 53 countries as endemic 
for trachoma [13, 14].
Several studies have demonstrated the occurren-
ce of trachoma in most parts of Brazil, with cases 
found in all regions and in different communities, 
both in urban centers and in rural areas, coastal 
cities or Amazon, as well as in remote indigenous 
communities. Since trachoma is most prevalent 
where hygiene conditions, lifestyle habits and so-
cioeconomic conditions are precarious added to a 
high density of flies looking for ocular areas [6, 15, 
16].
Cicle of the disease
The causative organism of trachoma is a Gram 
negative obligate intracellular bacteria Chlamydia 
trachomatis, which has a single chromosome from 
about 1 Mbp and multiple plasmid copies which 
functions as a virulence factor [17]. The endemic 
trachoma is caused by C. trachomatis serovars A, 
B, Ba and C. The genital tract infection is usually 
caused by serovars D to K, which can also infect the 
eye, causing ophthalmia neonatorum in newborns 
or adults conjunctivitis . The basis for the tissue tro-
pism of the serotypes was not fully elucidated [18].
It is known that the main form of transmission 
is direct, eye to eye, person to person. However, 
there is also a form of indirect transmission through 
contaminated objects (towels, handkerchiefs, pi-
llowcases). It is still possible that some insects such 
as housefly (Musca domestica) and / or eyeslickers 
(Hippelate ssp.), May act as mechanical vectors, 
contributing to the spread of the disease. Transmis-
sion is possible only when there are active lesions, 
being higher at the beginning of the disease and 
the occurrence of associated bacterial infections [3, 
9, 15].
After the infection with Chlamydia trachomatis 
there is an incubation period lasting about 5 to 12 
days. All individuals are susceptible to the disease, 
with children being the most sensitive, including the 
reinfection. The active trachoma (follicular or severe 
inflammatory trachoma) is more common in chil-
dren under 5 years and the prevalence can reach 
60% or more [19-21].
Pathophysiology
Trachoma is the result of a complex interaction 
between chlamydia infection and the immune res-
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ponse occurring over many years [22]. It begins in 
the form of follicular conjunctivitis (active follicular 
trachoma), with papillary hypertrophy and inflam-
matory cells infiltrating the conjunctiva (lympho-
cytes, macrophages, neutrophils, and plasma cells) 
punctuated by lymphoid follicles (B cells surroun-
ded by a mantle of T0 cells ) [23], which extends 
throughout the conjunctiva, especially in the upper 
tarsal conjunctiva.
In microscopic examination of the cornea reveals 
epithelial keratitis, subepithelial infiltrates and extent 
of the limbic vessels of the cornea. The inflammatory 
response to primary infection of the conjunctiva by 
Chlamydia trachomatis leads to a mild, self-limited 
frame conjunctivitis, called inclusion conjunctivitis. 
Not observed natural or acquired immunity to infec-
tion. Some experimental studies show that there is 
some resistance after the first episode of infection, 
but a partial resistance because after a new inocu-
lation, a new infection is developed [9, 24].
Trachoma is manifested in successive conjunctival 
reinfection because the individual lives where the 
disease is endemic, which favors the possibility of 
reinfection. Repeated infections lead to a hypersen-
sitive immune response to Chlamydia antigens, cau-
sing an inflammatory response becomes increasingly 
lush and leading to the succession of pathophysio-
logical phenomena that characterize trachoma [14, 
18] The infected children have increased expression 
of IFN-y and IL12p40 genes, suggesting an immune 
response mediated by lymphocytes (Th1) [25].
In hyperendemic areas, a subgroup of children, 
about 8-10%, seem to have constant infection and 
persistent severe inflammation (26-28) The inciden-
ce of scarring is nearly five times higher in these 
children than in children with active trachoma, but 
without severe inflammation [29]. In addition, scar 
formation can continue to develop in people living 
in areas that are not endemic [30], suggesting that 
the tissue damaged by infection with chlamydia can 
undergo progressive healing after injury by other 
bacterial pathogens [31].
Matrix metalloproteinases are an integral part of 
tissue homeostasis and are also involved in tissue 
destruction and fibrosis. These proteolytic enzymes 
are produced by inflammatory cells, fibroblasts and 
epithelium. In the active trachoma and scarring cau-
sed by trachoma occurs increasing the amount of 
matrix metalloproteinases 7, 9, and 12 [25, 32, 33]. 
These findings suggest a role for matrix metallo-
proteinases in scar formation, corneal opacities and 
loss of vision [34].
The fibrosis formed in response to the agent to 
exert traction upper eyelid, leading to a distortion, 
entropion, causing the eyelashes to touch the eye 
(trichiasis), which can cause ulcers. Therefore, sca-
rring and corneal opacification can lead to varying 
degrees of decreased visual acuity to blindness [1, 
3, 4, 7, 18]. Vision loss can occur within one year 
in up to one third of individuals with trichiasis un-
treated [34]. Even without loss of vision, trichiasis 
leads to substantial disability and reduced quality 
of life [35, 36].
Follicles also appear in the limbus region, when ne-
crosam, leave small depressions known as Herbert's 
pits. The appearance of keratitis in the upper limb 
region and neovascularization is often and is clini-
cally clinically as trachomatosus pannus [9].
The symptoms associated with inflammatory 
trachoma include tearing, foreign body sensation, 
photophobia and mild purulent discharge in small 
quantities, there will only be a lot of purulent when 
other bacterial conjunctivitis associated with tracho-
ma. In older and more serious infections conjuncti-
va can become thickened and edematous. A large 
proportion of cases of trachoma, especially among 
younger children are asymptomatic. Patients with 
entropion, trichiasis and those with corneal ulcera-
tions refer constant pain and intense photophobia 
[9, 16].
We observe two types of conjunctival inflam-
mation reaction in trachomatous: follicles and diffu-
se infiltration which can occur simultaneously. For 
purposes of classification, define degrees of tracho-
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matous inflammation of the conjunctiva, according 
to the criteria below: Predominantly Follicular inflam-
mation, trachoma Follicular - (TF); Predominantly 
Infiltration and Diffuse thickening of the conjuncti-
va, the Trachoma Intense-(IT). The other signals for 
diagnosis are: Healing Trachomatous Conjunctival 
Tarsal Superior-(TS); Trachomatous trichiasis-(TT); 
and Corneal - (CO).
All these signs are not mutually exclusive, but 
may also occur in the same patient and the same 
eye. Thus, one should always register their presen-
ce or absence. Trachoma is considered Follicular 
(TF) where there is the presence of at least five 
follicles of at least 0.5 mm diameter in the upper 
tarsal conjunctiva. Follicles are rounded elevations 
of the conjunctiva, bright and fainter than the 
conjunctiva around. They should be distinguished 
from changes caused by small scars and degene-
rative deposits in the conjunctiva. Small scars are 
not round, having angled edges, while the follicles 
have poorly defined borders. Degenerative depo-
sits include conjunctival aggregates, which are ye-
llow or white opaque masses with well-defined 
edges and cysts that appear as tiny clear bubbles 
in the conjunctiva [9, 15, 37].
Inflammation intense trachomatous (IT) is charac-
terized by marked thickening of the upper tarsal 
conjunctiva, which appears reddish wrinkled and 
not allowing the viewing of more than 50% deep 
tarsal vessels. In the healing Conjunctival Trachoma-
tous (TS), the conjunctiva has a milky appearance, 
fibrous, with straight edges, angular or stellate. It 
is considered Trichiasis Trachomatous (TT) when at 
least one of eyelashes rubs the eye when there is 
recent evidence removal of inverted eyelashes asso-
ciated with the presence of scars in the upper tarsal 
conjunctiva (TS) indicative of trachoma. The Cor-
neal (CO) trachomatous of origin, characterized by 
a clear view on the pupil with sufficient strength to 
obscure at least part of the pupillary margin [9, 37].
In endemic areas, children are infected early in 
life, developing TF and, depending on the reinfec-
tion frequency of severity and association with other 
bacterial conjunctivitis, may develop IT and later 
scarring conjunctival trachoma (TS). The prevalence 
of active inflammatory forms (TF and TI) decreases 
with age. So even in highly endemic areas, are rare 
cases of inflammatory trachoma among adults. The 
prevalence of cicatricial forms (TS) and sequelae (TT 
and CO) tends to increase with age [4, 7, 9].
Diagnosis
The diagnosis of Trachoma is essentially clinical, and 
is usually done by the external eye exam using bino-
cular loupe 2.5 fold increase. By examining the eye 
for diagnosis of trachoma, one should initially ob-
serve the eyelids and the cornea, verifying the pre-
sence or absence of entropion, trichiasis and corneal 
opacities. Then, should evert the upper eyelid and 
examine the central area of the tarsal conjunctiva, 
despising the edges of the eyelids and the corners. 
The normal conjunctiva is smooth, thin, transparent 
and pinkish in color [4, 9, 38].
In clinical diagnostics there is also the laboratory 
diagnosis of trachoma which is not considered es-
sential, since no other ocular diseases where it would 
be necessary to perform a differential diagnosis oc-
curs with the same epidemiological characteristics 
of trachoma, an endemic disease with spatial clus-
tering cases. The standard laboratory technique for 
the diagnosis of Chlamydia trachomatis is by the 
culture. Chlamydia is a microorganism obligatorily 
intracellular life, therefore only grows in cell culture. 
There are few laboratories in Brazil that routinely de-
velop cell cultures for diagnosis of Chlamydia. This 
is a complex and expensive procedure, which is not 
available for a routined use of the trachoma control 
program [9].
The differential diagnosis of trachoma is to be 
done considering the other follicular conjunctivitis, 
such as foliculoses; toxic follicular conjunctivitis; in-
clusion conjunctivitis; acute follicular conjunctivitis 
and other less common versions [9].
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Treatment
The goal of treatment is to cure the infection, with 
consequent interruption of the transmission chain 
of the disease. Antibiotics azithromycin oral or to-
pical tetracycline are used to reduce the number 
Chlamydia in endemic communities. Azithromycin 
(20 mg / kg to 1 g) is the preferred treatment. To-
pical treatment with tetracycline is made 1% - used 
ophthalmic ointment twice a day for six weeks, or in 
case of absence thereof, or hypersensitivity to drugs, 
sulfa - drop should be taken four times a day for six 
weeks. Patients with intense trachoma (TI) or cases 
of TF and TI do not respond well to topical medi-
cation, should make use of systemic treatment [14].
Despite the limited evidence in randomized trials, 
the overwhelming evidence from cohort studies, 
the rate of clinical disease and infection rates fall af-
ter the mass distribution of antibiotics (39-43). The 
mass distribution is indicated when the proportion 
of children aged 1-9 years with follicular trachoma 
(TF) is more than 10% in assessed community. In 
areas where the prevalence rate is 5-9%, it is re-
commended a focal approach. WHO recommends 
that, an initial prevalence of 10-30% mass distribu-
tion of antibiotics should continue for three years 
before a new prevalence study be conducted [14].
Clinical signs may persist long after the infection 
has cleared [44], and so the existence of clinical 
disease with no detectable infection has led some 
to question whether the clinical signs should be the 
criterion to determine when to stop treatment [45].
All cases of eyelid entropion and trachoma tri-
chiasis should be submitted to corrective surgical 
evaluation of the eyelids. The abrasive action of 
the cilia on the cornea is to be repaired by surgical 
correction of the eyelid margin (46). The trichiasis 
surgery slightly improves vision, reduces pain, and 
in some cases reduces the severity of corneal opa-
city [47-50]. The success of many surgical programs 
is hampered by the recurrence rates of infection 
which can be as high as 60% in three years [48, 
51-56].
Control and Prevention
It is clear that the treatment’s interventions should 
be coupled with promotion and prevention of tra-
choma. If the basic hygiene factors that allowed 
trachoma thrive on the site are not controlled, the 
disease will return once the mass distribution of 
antibiotics ceases. The trachoma interventions are 
planned at the district level with actions in the com-
munity and family level to interrupt transmission of 
the infection and minimize the reintroduction of 
infection in already treated communities. The local 
trachoma prevalence study is used to identify which 
programs are needed [14].
Studies dealing with the return of infection after 
use of azithromycin, show that the disease reap-
pears in households within 6 months, but can take 
up to a year to be evident in the community [57]. 
The measures to promote personal and family hy-
giene, such as: clean keep the faces of children and 
proper garbage disposal, contributes to decreased 
concentration of flies, may have a significant impact 
in reducing the prevalence and severity of cases [9, 
58, 59]. Overcrowding is a risk factor for trachoma, 
the number of children with active disease when 
increases proportionally if there are more people 
per room [60].
Routine lack of facial hygiene has been consis-
tently associated with trachoma [10, 61, 62]. Im-
provement in facial cleaning also decreases the se-
verity of active disease, probably by reducing the 
probability of reinfection [63]. Facial cleanliness and 
control strategies of environmental components for 
Trachoma are so important that were developed by 
WHO to "SAFE" strategy (S = corrective surgery for 
trichiasis; The antibiotics =; F = cleaning face; E = 
sanitation ), based on fairly simple measures that in-
volve personal care, accompanied by improvements 
in living conditions (4). But the proportion of cou-
ntries with trachoma that had implemented these 
components is daunting; while 61% have started 
the surgery and distribution of antibiotics programs, 
only 34% had also implemented facial cleanliness 
and environmental control measures adopted [64].
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The trachoma control policy should be integrated 
with both water treatment and sanitation programs, 
as well as health programs of children and adoles-
cents. Surgery and antibiotic distribution should be 
linked to hygiene and sanitation programs; and the 
implementation of hygiene and sanitation programs 
should be included in the monitoring and, conse-
quently, in the trachoma elimination certification 
[65].
Although there are funds for research related 
to neglected diseases, the knowledge produced 
does not translate into therapeutic advances, for 
example, new drugs, diagnostic methods and va-
ccines. One reason for this situation is the low in-
terest of the pharmaceutical industry on this issue, 
justified by the low potential lucrative perspective 
for the industry, since the target population is not 
wealthy and present, mostly in developing coun-
tries [4, 66].
The expectation is to create various strategies to 
mobilize prominent scientific groups in the coun-
try dedicated to the theme. Thus, new knowled-
ge about the different aspects - biological, clinical, 
social and others will be more eficiently produced, 
contributing to the fight against these diseases, 
both in respect of sick or exposed individuals, as 
well as to respect the communities and their living 
conditions [66).
Conclusion
Trachoma should be a concern of health systems, 
since it can lead to blindness, and is easy to diagno-
se and has a inexpensive initial treatment. Because 
it is a disease with easy contamination it is found 
in large proportions worldwide and reaches more 
people with low socioeconomic status and living 
in poverty, where there are few hygiene, garbage 
accumulation and lack of water. These conditions 
favor the increase of the number of flies that act 
as vectors of disease in those environments. To be 
able to think of the global eradication of trachoma, 
it is necessary the implementation of sanitation pro-
grams in disadvantaged areas. 
Another aspect worth mentioning is the impor-
tance of a detailed ophthalmological external phy-
sical examination. Health professionals are primarily 
responsible for providing guidelines for the pre-
vention and carrying out the diagnosis of forms of 
trachoma. Even in communities where the disease 
is combated with active systematic search and tre-
atment of cases and communicating, the disease is 
still present. The lack of knowledge on the subject 
leads to the current situation, and the training of he-
alth care professionals enables early recognition of 
trachoma, treatment and reduces the risk of com-
plications and blindness. Only then will be possible 
to meet the objective of extermination of Trachoma 
by the year 2020 as the WHO goal.
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